Enhancing the quality of life in visually impaired AMD patients

Article

An analysis of the AcrySof ReSTOR apodized diffractive intraocular lens

For many years we have induced pseudophakic myopia of 5 dioptres in our age-related macular degeneration (AMD) patients. This helped aid in near vision recovery and allowed patients to resume some activities in their lives that they were unable to previously do as a result of poor vision. It also avoided spectacle induced loss of contrast sensitivity. While our patients were pleased with their near acuity, they were displeased with the high myopic correction for distance acuity.

Low vision aid

While the lens is not indicated for this use, I realized that I could use the lens as a low vision aid. Under photopic conditions, a -2.00 distance refraction provides a near equivalent of +5.20 D with a best focus of 20 cm. The AcrySof ReSTOR lens technique does not reduce uncorrected distance acuity nearly as much as a -5.0 D myopia inducing monofocal lens. The patients were much happier now that they only needed a -2.0 D distance correction.

Our first two AMD patients that were implanted with the ReSTOR lens were absolutely ecstatic, so we started a pilot study. The pilot study was a prospective series of cataract patients with vision loss from AMD, who received an offlabel AcrySof ReSTOR IOL following phacoemulsification. Surgery was planned for a desired postoperative refraction of -2.0 to -3.0 spherical equivalent. This pilot study also demonstrated that not only was the patients' uncorrected near acuity improved, but also that many aspects of their quality of life improved; therefore a formal, multicentre study was conducted.

The 6-month multicentre included 20 eyes of 13 patients that were more than 50 years of age with stable, dry macular degeneration or with macular degeneration associated with disciform scarring per the doctor's examination. Near and distance Snellen visual acuities with and without correction were collected, as well as subjective patient quality of life statements collected pre and postoperatively. The National Eye Institute Visual Function Questionnaire (VFQ-25 Version 2000) was also administered to the patient's pre- and postoperatively.3

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.